Welcome to our dedicated page for Aptevo Therapeutics SEC filings (Ticker: APVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aptevo Therapeutics Inc. (APVO) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries to help interpret key points. As a Nasdaq-listed, clinical-stage biotechnology company focused on bispecific and trispecific immunotherapies, Aptevo uses SEC filings to report on its financial condition, capital structure, and material business developments.
Investors researching APVO can review Form 10-K annual reports and Form 10-Q quarterly reports (when available) to understand operating expenses, research and development spending, and liquidity. These periodic reports typically discuss the progress of clinical programs such as the RAINIER Phase 1b/2 trial of mipletamig in frontline acute myeloid leukemia and the development of ALG.APV-527 and other pipeline candidates built on the ADAPTIR and ADAPTIR-FLEX platforms.
Form 8-K current reports are especially relevant for Aptevo, as they disclose material events including quarterly financial results, equity financings, amendments to rights agreements, clinical milestones, and Nasdaq listing updates. Recent 8-Ks, for example, have referenced financial results for specific quarters, expansion of the CD3-engaging pipeline, and confirmation of compliance with Nasdaq stockholders’ equity requirements.
Aptevo’s registration statements, such as the Form S-1 filed in connection with a Standby Equity Purchase Agreement, provide detail on financing structures, potential share issuances, and risk factors. Proxy materials like the DEF 14A definitive proxy statement describe corporate governance matters, stock incentive plans, and stockholder approvals for actions such as reverse stock splits and equity facilities.
On Stock Titan, AI tools summarize lengthy filings to highlight items such as changes in stockholders’ equity, new financing agreements, and disclosures about the bispecific and trispecific oncology pipeline. Users can also track Form 4 insider transaction reports when filed, gaining visibility into equity transactions by Aptevo’s officers and directors.
By using this APVO filings page, investors can quickly navigate Aptevo’s SEC reporting history, from financial updates to clinical and capital markets disclosures, with AI-generated insights that clarify complex regulatory documents.
Aptevo Therapeutics is registering up to 7,075,471 shares of common stock for resale by YA II PN, Ltd. under a standby equity purchase agreement. These shares will be issued to YA over time as Aptevo sells stock to it under a $60.0 million commitment, with purchase prices set at 96% of the lowest of three daily volume-weighted average prices in each pricing period. Aptevo will not receive proceeds from YA’s resale of the registered shares, but may raise capital from its direct sales to YA during a commitment period running to January 8, 2029, subject to ownership and exchange caps. As of September 30, 2025, Aptevo had 767,164 shares outstanding, so full issuance of all 7,075,471 shares reserved for this facility would represent a very large potential increase in its share count.
Aptevo Therapeutics is asking stockholders to approve three items at a virtual special meeting on February 18, 2026. The first would adopt an amended and restated certificate of incorporation that consolidates prior amendments, updates the company’s address, confirms perpetual duration, clarifies certain Delaware law voting provisions, and formally includes the designation of Series A Junior Participating Preferred Stock. The second seeks approval, under Nasdaq rules, for the potential issuance of 19.99% or more of the company’s common stock outstanding as of January 8, 2026 under a $60.0 million Standby Equity Purchase Agreement with Yorkville, which allows Aptevo to draw capital over 36 months at a discount to market VWAP. The third proposal would allow the meeting to be adjourned to solicit additional proxies if there are not enough votes for Proposals 1 or 2. There were 997,830 shares of common stock outstanding and entitled to vote as of January 9, 2026.
Aptevo Therapeutics Inc. has called a virtual special stockholder meeting on February 18, 2026 to vote on three proposals. The first would adopt an amended and restated certificate of incorporation that consolidates prior amendments, updates the company’s addresses, clarifies certain Delaware law voting mechanics, restates multiple past reverse stock splits, and formally includes the designation of Series A Junior Participating Preferred Stock, largely as technical and administrative changes.
The second proposal seeks approval under Nasdaq rules for the potential issuance of 19.99% or more of Aptevo’s common stock as of January 8, 2026 pursuant to a Standby Equity Purchase Agreement with Yorkville, which allows Aptevo to sell up to $60.0 million of common stock over 36 months, at 96% of the lowest volume-weighted average price over a three-day period for each draw. As of the January 9, 2026 record date, Aptevo had 997,830 shares of common stock outstanding, and a 19.99% cap currently limits issuances below a minimum price of $8.753 per share to 199,466 shares absent stockholder approval. The company states this facility is intended to provide flexible capital for working capital, operating expenses and business development, and warns that failure to approve the share issuance could impair funding and force it to seek potentially more dilutive alternatives.
The third proposal would allow adjournment of the meeting, if necessary, to solicit more proxies in favor of the charter amendment and SEPA share issuance. The board recommends that stockholders vote “FOR” all three proposals.
Aptevo Therapeutics Inc. entered into a $60.0 million Standby Equity Purchase Agreement with Yorkville, giving Aptevo the right, but not the obligation, to sell common stock to Yorkville over a 36‑month period through individual advances. Shares for each advance would be priced at 96% of the lowest daily VWAP over a three‑trading‑day period after Aptevo delivers an advance notice, and Aptevo may set a minimum acceptable price.
The agreement includes a 2.00% commitment fee on the $60.0 million, payable in five quarterly installments, and a $25,000 structuring fee to Yorkville. Under Nasdaq rules, issuance is capped at 199,466 shares, representing 19.99% of shares outstanding as of signing, unless shareholder approval is obtained or pricing conditions are met, and Yorkville’s beneficial ownership is limited to 9.99% of Aptevo’s outstanding common stock. Yorkville’s purchase obligation depends on an SEC registration statement for the advance shares being filed and declared effective.
Aptevo Therapeutics Inc. is registering up to 6,903,755 shares of common stock for resale by YA II PN, LTD. under a standby equity purchase agreement. These shares relate to an up to
As of September 30, 2025, Aptevo had 13,808,966 shares outstanding, and if all registered shares are issued, total shares outstanding would rise to 20,712,721. The company has already raised approximately
Aptevo Therapeutics (APVO) director reported an open‑market purchase on Form 4. The filing shows a buy of 13,513 shares of common stock at $1.49 per share on 11/10/2025 (Transaction Code: P). Following the trade, the director beneficially owns 13,514 shares, held directly.
Aptevo Therapeutics (APVO) filed its Q3 2025 10‑Q, reporting a quarterly net loss of $7.5 million and a nine‑month net loss of $20.2 million. Operating expenses rose as R&D reached $4.0 million and G&A was $3.6 million for the quarter. A warrant down‑round adjustment recorded a $1.5 million deemed dividend, increasing loss attributable to common stockholders.
Cash and cash equivalents were $21.1 million at September 30, 2025, up from $8.7 million year‑end, driven by $32.7 million year‑to‑date financing cash inflows. The company raised $18.7 million, net in Q3 via its SEPA with Yorkville and ATM program, plus $4.1 million net after quarter‑end. Stockholders’ equity improved to $17.4 million. Year‑to‑date operating cash use was $20.4 million.
Financing capacity includes $10.0 million remaining under the SEPA; the ATM currently has no availability under Form S‑3 I.B.6 limits. Common warrants outstanding totaled 12,535,033, all exercisable. The company effected a 1‑for‑20 reverse split in May 2025. Clinical updates highlight mipletamig AML combination data with high remission rates and no CRS among evaluable frontline patients. Shares outstanding were 16,850,494 as of November 6, 2025.
Aptevo Therapeutics Inc. (APVO) filed an 8-K stating it furnished a press release announcing its financial results for the period ended September 30, 2025. The press release is included as Exhibit 99.1.
The company notes the information is being furnished under Item 2.02 and is not deemed “filed” for purposes of the Exchange Act or the Securities Act, and will not be incorporated by reference into other SEC filings except by specific reference.
Aptevo Therapeutics entered into Amendment No. 5 to its Rights Agreement, extending the definition of the “Final Expiration Date” to October 29, 2026. The Rights Agreement covers contingent rights to purchase one one‑thousandth of a share of the company’s Series A Junior Participating Preferred Stock. The change is disclosed as a material modification to security holder rights under Item 3.03.
FAQ
What is the current stock price of Aptevo Therapeutics (APVO)?
What is the market cap of Aptevo Therapeutics (APVO)?
